These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
327 related articles for article (PubMed ID: 37253487)
21. Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study. Szebeni GJ; Gémes N; Honfi D; Szabó E; Neuperger P; Balog JÁ; Nagy LI; Szekanecz Z; Puskás LG; Toldi G; Balog A Front Immunol; 2022; 13():846248. PubMed ID: 35432314 [TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Heshin-Bekenstein M; Ziv A; Toplak N; Hagin D; Kadishevich D; Butbul YA; Saiag E; Kaufman A; Shefer G; Sharon O; Pel S; Elkayam O; Uziel Y Rheumatology (Oxford); 2022 Nov; 61(11):4263-4272. PubMed ID: 35179569 [TBL] [Abstract][Full Text] [Related]
23. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232 [TBL] [Abstract][Full Text] [Related]
24. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19? Scaggs Huang F J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545 [TBL] [Abstract][Full Text] [Related]
27. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD; Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076 [TBL] [Abstract][Full Text] [Related]
28. Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases. Cheung MW; Dayam RM; Shapiro JR; Law JC; Chao GYC; Pereira D; Goetgebuer RL; Croitoru D; Stempak JM; Acheampong L; Rizwan S; Lee JD; Jacob L; Ganatra D; Law R; Rodriguez-Castellanos VE; Kern-Smith M; Delgado-Brand M; Mailhot G; Haroon N; Inman RD; Piguet V; Chandran V; Silverberg MS; Watts TH; Gingras AC J Immunol; 2023 Aug; 211(3):351-364. PubMed ID: 37326480 [TBL] [Abstract][Full Text] [Related]
29. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents. Blain H; Tuaillon E; Gamon L; Pisoni A; Miot S; Picot MC J Am Med Dir Assoc; 2022 May; 23(5):750-753. PubMed ID: 35311651 [TBL] [Abstract][Full Text] [Related]
30. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D Front Immunol; 2022; 13():846753. PubMed ID: 35309297 [TBL] [Abstract][Full Text] [Related]
31. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K Front Immunol; 2021; 12():704773. PubMed ID: 34220867 [TBL] [Abstract][Full Text] [Related]
32. Results of the Stop the Spread Ottawa (SSO) cohort study: a Canadian urban-based prospective evaluation of antibody responses and neutralisation efficiency to SARS-CoV-2 infection and vaccination. Keeshan A; Galipeau Y; Heiskanen A; Collins E; McCluskie PS; Arnold C; Saginur R; Booth R; Little J; McGuinty M; Buchan CA; Crawley A; Langlois MA; Cooper C BMJ Open; 2023 Oct; 13(10):e077714. PubMed ID: 37907304 [TBL] [Abstract][Full Text] [Related]
33. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data. Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939 [TBL] [Abstract][Full Text] [Related]
34. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections. Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831 [TBL] [Abstract][Full Text] [Related]
35. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252 [TBL] [Abstract][Full Text] [Related]
36. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab. Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299 [TBL] [Abstract][Full Text] [Related]
37. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Alexander JL; Kennedy NA; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Liu Z; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Goodhand JR; Hart AL; Lees CW; Ahmad T; Powell N; Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):342-352. PubMed ID: 35123676 [TBL] [Abstract][Full Text] [Related]
38. Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies. Gressens SB; Fourati S; Le Bouter A; Le Bras F; Dupuis J; Hammoud M; El Gnaoui T; Gounot R; Roulin L; Belhadj K; Haioun C; Gallien S; Melica G; Lemonnier F Clin Microbiol Infect; 2022 Jun; 28(6):885.e7-885.e11. PubMed ID: 35259530 [TBL] [Abstract][Full Text] [Related]
39. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients. Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E Front Immunol; 2022; 13():907615. PubMed ID: 35812459 [TBL] [Abstract][Full Text] [Related]
40. Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study. Ørbo HS; Bjørlykke KH; Sexton J; Jyssum I; Tveter AT; Christensen IE; Mjaaland S; Kvien TK; Grødeland G; Kro GB; Jahnsen J; Haavardsholm EA; Munthe LA; Provan SA; Vaage JT; Goll GL; Jørgensen KK; Syversen SW RMD Open; 2024 Apr; 10(2):. PubMed ID: 38599653 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]